Ann Hepatobiliary Pancreat Surg.  2020 Nov;24(4):421-430. 10.14701/ahbps.2020.24.4.421.

Bridging and downstaging role of trans-arterial radio-embolization for expected small remnant volume before liver resection for hepatocellular carcinoma

• Shehta A
• Lee JM
• Suh KS
• Kim HC
• Hong SK
• Cho JH
• Yi NJ
• Lee KW

• KMID: 2508850
• DOI: http://doi.org/10.14701/ahbps.2020.24.4.421

Abstract

Backgrounds/Aims
To evaluate our initial experience of bridging role of trans-arterial radio-embolization (TARE) before major hepatectomy for hepatocellular carcinoma (HCC) in risky patients with small expected remnant liver volume (ERLV).
Methods
We reviewed the data of patients with HCC who underwent major hepatectomy after TARE during the period between March and December 2017. Patients included had uni-lobar large HCC (＞5 cm) requiring major hepatectomy with small ERLV.
Results
Five patients were included in our study. All patients were Child Pugh class A. A single session of TARE was applied in all patients. None developed any adverse events related to irradiation. The mean tumor size at baseline was 8.4 cm and 6.1 cm after TARE (p=0.077). The mean % of tumor shrinkage was 24.5%. ERLV improved from 354.6 ml at baseline to 500.8 ml after TARE (p=0.012). ERLV percentage improved from 27.2% at baseline to 38.1% after TARE (p=0.004). The mean % of ERLV was 39.5%. The mean interval time between TARE and resection was 99.6 days. Four patients (80%) underwent right hemi-hepatectomy and one patient (20%) underwent extended right hemi-hepatectomy. The mean operation time was 151 minutes, and mean blood loss was 56 ml. The mean hospital stay was 13.8 days, and one patient (20%) developed postoperative morbidity. After a mean follow-up of 15 months, all patients were alive with no recurrence.
Conclusions
Yttrium-90 TARE can play a bridging role before major hepatectomy for borderline resectable HCC in risky patients with small ERLV.

Keyword

Trans-arterial radio-embolization; Major liver resection; Small remnant liver volume

Figure

• 

  Fig. 1 Management algorithm of the study patients. TARE, trans-arterial radio-embolization; CT, computed tomography; LFT, liver function tests; AFP, alpha fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist-II.

• 

  Fig. 2 (A-F) Computed tomography photos showing gradual tumor shrinkage (red line) and increased remnant liver volume (blue zone) after yettrium-90 trans- arterial radioembolization. (A and D) At baseline evaluation, (B and E) 4 weeks after trans-arterial radioembolization, and (C and F) before liver resection. (G-I) Operative view of right hemi-hepatectomy after yettrium-90 trans- arterial radioembolization. (G) Initial exposure with noted demarcation and inflammation on the right hemi-liver. (H) Pedicle dissection and individual control of inflow structures. (I) Parenchymatous division by cavitron ultrasonic suction aspirator.

• 

  Fig. 3 Changes in serum liver functions and tumor markers during management protocol. (A) Changes in serum bilirubin. (B) Changes in serum alanine aminotransferase (ALT). (C) Changes in serum aspartate aminotransferase (AST). (D) Changes in serum alpha fetoprotein (AFP). (E) Changes in serum protein induced by vitamin K absence or antagonist-II (PIVKA-II). TARE, trans-arterial radio-embolization; Op, operation.

Reference

1. Byam J, Renz J, Millis JM. 2013; Liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2:22–30. DOI: 10.21037/hbsn.2016.08.03. PMID: 27826557. PMCID: PMC5075829.

2. Li X, Huang L, Leng X. 2018; Analysis of prognostic factors of more/equal to 10 years of survival for liver cancer patients after liver transplantation. J Cancer Res Clin Oncol. 144:2465–2474. DOI: 10.1007/s00432-018-2756-8. PMID: 30259149. PMCID: PMC6244647.

3. Cauchy F, Soubrane O, Belghiti J. 2014; Liver resection for HCC: patient's selection and controversial scenarios. Best Pract Res Clin Gastroenterol. 28:881–896. DOI: 10.1016/j.bpg.2014.08.013. PMID: 25260315.

4. Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunvén P, et al. 1990; Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery. 107:521–527. PMID: 2333592.

5. de Graaf W, van den Esschert JW, van Lienden KP, van Gulik TM. 2009; Induction of tumor growth after preoperative portal vein embolization: is it a real problem? Ann Surg Oncol. 16:423–430. DOI: 10.1245/s10434-008-0222-6. PMID: 19050974.

6. Heinrich S, Jochum W, Graf R, Clavien PA. 2006; Portal vein ligation and partial hepatectomy differentially influence growth of intrahepatic metastasis and liver regeneration in mice. J Hepatol. 45:35–42. DOI: 10.1016/j.jhep.2006.02.020. PMID: 16698111.

7. Hayashi S, Baba Y, Ueno K, Nakajo M, Kubo F, Ueno S, et al. 2007; Acceleration of primary liver tumor growth rate in embolized hepatic lobe after portal vein embolization. Acta Radiol. 48:721–727. DOI: 10.1080/02841850701424514. PMID: 17729001.

8. Aoki T, Imamura H, Hasegawa K, Matsukura A, Sano K, Sugawara Y, et al. 2004; Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg. 139:766–774. DOI: 10.1001/archsurg.139.7.766. PMID: 15249411.

9. Mason MC, Massarweh NN, Salami A, Sultenfuss MA, Anaya DA. 2015; Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma. HPB (Oxford). 17:1137–1144. DOI: 10.1111/hpb.12487. PMID: 26374137. PMCID: PMC4644367.

10. Blackburn H, West S. 2016; Management of postembolization syndrome following hepatic transarterial chemoembolization for primary or metastatic liver cancer. Cancer Nurs. 39:E1–E18. DOI: 10.1097/NCC.0000000000000302. PMID: 26484962.

11. Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson AB, Ganger D, et al. 2013; Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol. 58:73–80. DOI: 10.1016/j.jhep.2012.09.003. PMID: 23000237. PMCID: PMC3527660.

12. Wang EA, Stein JP, Bellavia RJ, Broadwell SR. 2017; Treatment options for unresectable HCC with a focus on SIRT with Yttrium- 90 resin microspheres. Int J Clin Pract. 71:e12972. DOI: 10.1111/ijcp.12972. PMID: 28758319.

13. Gabr A, Abouchaleh N, Ali R, Baker T, Caicedo J, Katariya N, et al. 2018; Outcomes of surgical resection after radioembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 29:1502–1510. e1. DOI: 10.1016/j.jvir.2018.06.027. PMID: 30268638.

14. Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, et al. 2013; Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 59:1029–1036. DOI: 10.1016/j.jhep.2013.06.015. PMID: 23811303. PMCID: PMC5085290.

15. Lewandowski RJ, Donahue L, Chokechanachaisakul A, Kulik L, Mouli S, Caicedo J, et al. 2016; 90Y radiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol. 114:99–105. DOI: 10.1002/jso.24269. PMID: 27103352.

16. Yang X, Yu HC, Choi Y, Lee W, Yang J, Hwang H, et al. 2014; Development and usability testing of Dr. Liver^TM: a user-centered 3D virtual liver surgery planning system. Proc Hum Factors Ergon Soc Annu Meet. 58:698–702. DOI: 10.1177/1541931214581163.

17. Kim HC, Kim YJ, Paeng JC, Chung JW. 2018; Yttrium-90 radioembolization of the right inferior phrenic artery in 20 patients with hepatocellular carcinoma. J Vasc Interv Radiol. 29:556–563. DOI: 10.1016/j.jvir.2017.10.010. PMID: 29373246.

18. Kim HC, Kim YJ, Lee JH, Suh KS, Chung JW. 2018; Feasibility of boosted radioembolization for hepatocellular carcinoma larger than 5 cm. J Vasc Interv Radiol. 30:1–8. DOI: 10.1016/j.jvir.2018.07.002. PMID: 30293734.

19. Lencioni R, Llovet JM. 2010; Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 30:52–60. DOI: 10.1055/s-0030-1247132. PMID: 20175033.

20. Dindo D, Demartines N, Clavien PA. 2004; Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 240:205–213. DOI: 10.1097/01.sla.0000133083.54934.ae. PMID: 15273542. PMCID: PMC1360123.

21. Gluer AM, Cocco N, Laurence JM, Johnston ES, Hollands MJ, Pleass HC, et al. 2012; Systematic review of actual 10-year survival following resection for hepatocellular carcinoma. HPB (Oxford). 14:285–290. DOI: 10.1111/j.1477-2574.2012.00446.x. PMID: 22487065. PMCID: PMC3384847.

22. Bruix J, Sherman M. 2011; Management of hepatocellular carcinoma: an update. Hepatology. 53:1020–1022. DOI: 10.1002/hep.24199. PMID: 21374666. PMCID: PMC3084991.

23. Forner A, Llovet JM, Bruix J. 2012; Hepatocellular carcinoma. Lancet. 379:1245–1255. DOI: 10.1016/S0140-6736(11)61347-0. PMID: 29307467.

24. Henry LR, Hostetter RB, Ressler B, Bowser I, Yan M, Vaghefi H, et al. 2015; Liver resection for metastatic disease after y90 radioembolization: a case series with long-term follow-up. Ann Surg Oncol. 22:467–474. DOI: 10.1245/s10434-014-4012-z. PMID: 25190114.

25. Salem R, Mazzaferro V, Sangro B. 2013; Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology. 58:2188–2197. DOI: 10.1002/hep.26382. PMID: 23512791. PMCID: PMC3732811.

26. Fidelman N, Kerlan RK Jr. 2015; Transarterial chemoembolization and 90Y radioembolization for hepatocellular carcinoma: review of current applications beyond intermediate-stage disease. AJR Am J Roentgenol. 205:742–752. DOI: 10.2214/AJR.15.14802. PMID: 26397322.

27. Wang LM, Jani AR, Hill EJ, Sharma RA. 2013; Anatomical basis and histopathological changes resulting from selective internal radiotherapy for liver metastases. J Clin Pathol. 66:205–211. DOI: 10.1136/jclinpath-2012-201231. PMID: 23162108. PMCID: PMC3595145.

28. Kim RD, Kim JS, Watanabe G, Mohuczy D, Behrns KE. 2008; Liver regeneration and the atrophy-hypertrophy complex. Semin Intervent Radiol. 25:92–103. DOI: 10.1055/s-2008-1076679. PMID: 21326550. PMCID: PMC3036484.

29. Edeline J, Lenoir L, Boudjema K, Rolland Y, Boulic A, Le Du F, et al. 2013; Volumetric changes after 90y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting? Ann Surg Oncol. 20:2518–2525. DOI: 10.1245/s10434-013-2906-9. PMID: 23494107.

30. Shindoh J, D Tzeng CW, Vauthey JN. 2012; Portal vein embolization for hepatocellular carcinoma. Liver Cancer. 1:159–167. DOI: 10.1159/000343829. PMID: 24159580. PMCID: PMC3760463.

31. Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, et al. 2003; Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 237:208–217. DOI: 10.1097/01.SLA.0000048447.16651.7B. PMID: 12560779. PMCID: PMC1522143.

32. Riaz A, Awais R, Salem R. 2014; Side effects of yttrium-90 radioembolization. Front Oncol. 4:198. DOI: 10.3389/fonc.2014.00198. PMID: 25120955. PMCID: PMC4114299.

33. Nguyen KT, Gamblin TC, Geller DA. 2009; World review of laparoscopic liver resection-2,804 patients. Ann Surg. 250:831–841. DOI: 10.1097/SLA.0b013e3181b0c4df. PMID: 19801936.